Livanova usa, inc.Submits this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation, based on information that livanova has obtained, but may not have been able to investigate or verify prior to the date the report was required by the fda.This report does not constitute an admission, or a conclusion by fda or anyone else, that the device, livanova, or livanovas employees caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any "defects¿ or "malfunctions¿.These words are incorporated into the fda 3500a medwatch form by the fda, and livanova objects to their use.
|
It was reported that patients battery reached 25% indicator prematurely.The device showed 18-25% battery life remaining after 7 months of therapy.Settings and diagnostics from two dates were provided.It was also reported that they are seeking replacement.Device history records were reviewed.The device passed all functional and quality testing prior to distribution.No recent surgeries, electrocautery, or unusual events occurred that could have contributed to the event.Tablet data was received and a decoder review was completed.There is suspicion that the voltage will rebound above the 2.85v 25% indicator threshold but not yet confirmed.Follow up has been initiated for updated system diagnostics.No known surgical intervention has occurred to date.No other relevant information has been received to date.
|